EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A nomogram based on TFE3 IHC results and clinical factors as a preliminary screening scheme for TFE3 ‐rearranged renal cell carcinoma

Pengju Li, Quanhui Xu, Minyu Chen, Jiangquan Zhu, Yinghan Wang, Mukhtar A Mumin, Kangbo Huang, Zeying Jiang, Hui Liang iD, Qiong Deng, Zhu Wang, Bing Liao und 4 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.6813 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Pengju Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Provincial Science and Technology Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

TFE3 immunohistochemistry (TFE3‐IHC) is controversial in the diagnosis of TFE3‐rearranged renal cell carcinoma (TFE3‐rearranged RCC). This study is to investigate the accuracy and sensitivity of IHC and establish a predictive model to diagnose TFE3‐rearranged RCC.

Methods

Retrospective analysis was performed by collecting IHC and fluorescence in situ hybridization (FISH) results from 228 patients. IHC results were evaluated using three scoring systems. Scoring system 1 is graded based on nuclear staining intensity, scoring system 2 is graded based on the percentage of stained tumor cell nuclei, and scoring system 3 is graded based on both the nuclear staining intensity and the percentage. We collected patients' IHC results and clinical information. Important variables were screened based on univariate logistic regression analysis. Then, independent risk factors were established through multivariate logistic regression, and a nomogram model was constructed. The model was validated in internal test set and external validation set. The receiver operating characteristic curve (ROC curve), calibration curve, and decision curve analysis (DCA) were generated to assess discriminative ability of the model.

Results

The accuracy of IHC based on three scoring systems were 0.829, 0.772, and 0.807, respectively. The model included four factors including age, gender, lymph node metastasis and IHC results. Area under the curve (AUC) values were 0.935 for the training set, 0.934 for the internal test set, 0.933 for all 228 patients, and 0.916 for the external validation set.

Conclusions

TFE3 IHC has high accuracy in the diagnosis of TFE3‐rearranged RCC. Clinical information such as age and lymph node metastasis are independent risk factors, which can be used as a supplement to the results of TFE3 IHC. This study confirms the value of IHC in the diagnosis of TFE3‐rearranged RCC. The accuracy of the diagnosis can be improved by incorporating IHC with other clinical risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansNomogramsRetrospective StudiesIn Situ Hybridization, FluorescenceLymphatic MetastasisTranslocation, GeneticBasic Helix-Loop-Helix Leucine Zipper Transcription Factors

Stichwörter der Autor:innen

TFE3-rearranged renal cell carcinomadiagnosisfluorescence in situ hybridizationimmunohistochemistry

Substanzen

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsTFE3 protein, human

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Urology, The Cancer Center of Sun Yat-sen University, Guangzhou, China.
  • Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Urology, Affiliated Longhua People's Hospital, Southern Medical University, Shenzhen, China.
  • Department of Pathology, The Cancer Center of Sun Yat-sen University, Guangzhou, China.
  • Department of Urology, Jiangmen Central Hospital, Jiangmen, China.

ORCID-Profile: Hui Liang, Junhang Luo

Förderung

  • Guangdong Provincial Science and Technology Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Li, P., Xu, Q., Chen, M., Zhu, J., Wang, Y., Mumin, M. A., Huang, K., Jiang, Z., Liang, H., Deng, Q., Wang, Z., Liao, B., Chen, W., Cao, Y., Cao, J., & Luo, J. (2024). A nomogram based on TFE3 IHC results and clinical factors as a preliminary screening scheme for TFE3 ‐rearranged renal cell carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.6813

Vancouver

Li P, Xu Q, Chen M, Zhu J, Wang Y, Mumin MA, et al. A nomogram based on TFE3 IHC results and clinical factors as a preliminary screening scheme for TFE3 ‐rearranged renal cell carcinoma. Cancer Medicine. 2024. doi:10.1002/cam4.6813

BibTeX
@article{Li2024,
  author = {Li, Pengju and Xu, Quanhui and Chen, Minyu and Zhu, Jiangquan and Wang, Yinghan and Mumin, Mukhtar A and Huang, Kangbo and Jiang, Zeying and Liang, Hui and Deng, Qiong and Wang, Zhu and Liao, Bing and Chen, Wenfang and Cao, Yun and Cao, Jiazheng and Luo, Junhang},
  title = {A nomogram based on TFE3 IHC results and clinical factors as a preliminary screening scheme for TFE3 ‐rearranged renal cell carcinoma},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6813}
}
Kostenlos starten →